**H**EALTH INNOVATION NE**X**T GENERATION **P**AYMENT & PRICING MODELS (**HI-PRIX**): Balancing Sustainability of Innovation with Sustainability of Health Care



M5: Literature review on the approaches and consequences of including environmental impacts in pricing and reimbursement based on economic evaluations

WP3: Widening the scope of economic evaluations for pricing and reimbursement decisions: the role of indirect medical cost and environmental impact

Authors: Vittoria Ardito (UB), Helen Banks (UB), Niccolò Cusumano (UB), Rosanna Tarricone (UB)



This project has received funding from the European Union's Horizon Europe research and innovation programme under Grant Agreement number 101095593



# COVER PAGE

| Project Acronym        | HI-PRIX  |  |  |
|------------------------|--|--|--|
| Project Title          | Health Innovation Next Generation Payment & Pricing<br>Models: Balancing Sustainability of Innovation with<br>Sustainability of Health Care  |  |  |
| Project Coordinator    | Oriana Ciani<br>oriana.ciani@unibocconi.it   |  |  |
| Grant Agreement number | 101095593  |  |  |
| Project Duration       | January 2023 – December 2025 (36 months)   |  |  |
| Milestone No.          | M5 – Literature review on the approaches and<br>consequences of including environmental impacts in<br>pricing and reimbursement based on economic<br>evaluations                           |  |  |
| Work Package           | WP3 – Widening the scope of economic evaluations for<br>pricing and reimbursement decisions: the role of indirect<br>medical cost and environmental impact                                 |  |  |
| Task                   | T3.2 – Literature review and theoretical analysis on the<br>approaches and consequences of including<br>environmental impact in pricing and reimbursement<br>based on economic evaluations |  |  |
| Lead Beneficiary       | UB   |  |  |
| Status                 | Submission   |  |  |
| Dissemination level    | PU (Public)  |  |  |
| Туре                   | R – Report   |  |  |
| Due date of milestone  | 30 June 2023 (M6)  |  |  |





| Author(s) & Organization(s)   | Vittoria Ardito (UB), Helen Banks (UB), Niccolò Cusumano<br>(UB), Rosanna Tarricone (UB) |
|-------------------------------|--|
| Reviewer(s) & Organization(s) | Oriana Ciani (UB)  |
| Contact                       | Vittoria.ardito@sdabocconi.it  |
| Project Acronym               | HI-PRIX  |

| File History |            |                                   |   |                   |
|--------------|------------|-----------------------------------|---|-------------------|
| Version      | Date       | Status                            | Author                                    | Review            |
| 0.1          | 15.04.2023 | Draft structure                   | Vittoria Ardito (UB),<br>Helen Banks (UB) |                   |
| 0.2          | 30.04.2023 | Specific<br>contribution<br>added | Niccolò Cusumano<br>(UB)                  |                   |
| 0.3          | 10.05.2023 | Critical review                   | Rosanna Tarricone<br>(UB)                 |                   |
| 0.4          | 30.06.2023 | Final version<br>submitted        | All authors                               | Oriana Ciani (UB) |



HI-PRIX

M5: Literature review on the approaches and consequences of including environmental impacts in pricing and reimbursement based on economic evaluations WP3

## Table of contents

| COVER PAGE   | 2  |
|--|----|
| ABBREVIATIONS  | 5  |
| 1. INTRODUCTION  | 6  |
| 1.1 MILESTONE IN THE CONTEXT OF HI-PRIX                            | 6  |
| 1.2 Objectives   | 6  |
| 2 BACKGROUND INFORMATION   | 7  |
| 2.1 Context  | 7  |
| 2.2 Objectives   | 8  |
| 2.3 Definitions  | 8  |
| 3. METHODOLOGY   | 9  |
| 4. RESULTS   | 11 |
| 4.1 Overview of results  | 11 |
| 4.2 Overview of the studies  |    |
| 4.3 Assessment of the environmental impacts of health technologies | 13 |
| 4.4 INTEGRATION OF THE ENVIRONMENTAL IMPACT IN HTA                 | 15 |
| 4.5 Conclusive remarks   | 17 |
| REFERENCES   |    |





# Abbreviations

AIHTA: Austrian Institute for Health Technology Assessment BIA: budget impact analysis CADTH: Canada's Drug and Health Technology Agency CO<sub>2</sub>: carbon dioxide CBA: cost benefit analysis CEA: cost effectiveness analysis CEASS: comprehensive environmental assessment CUA: cost utility analysis EEIOA: environmental extended input output analysis EU: European Union HTA: health technology assessment HRQOL: health-related quality of life ICER: incremental cost-effectiveness ratio GHG: greenhouse gas LCA: life cycle analysis MCDA: multi-criteria decision analysis NICE: National Institute on Health and Care Excellence PRISMA-ScR: Preferred Reporting Items for Systematic Reviews and Meta-Analyses-Extension for **Scoping Reviews** UK: United Kingdom





# 1. Introduction

# 1.1 Milestone in the context of HI-PRIX

This **report has been produced as part of the activities foreseen under WP3** "Widening the scope of economic evaluations for pricing and reimbursement decisions: the role of indirect medical and environmental costs", and **specifically under Task 3.2** "Literature review and theoretical analysis on the approaches and consequences of including environmental impact in pricing and reimbursement based on economic evaluations".

There are a number of ways in which the evidence base for pricing and reimbursement decision can be widened. Broadening the dimensions of value in healthcare by incorporating further value elements in established cost-effectiveness analysis (CEA) is a topic of discussion. For instance, in 2018 an ISPOR Special Task Force was appointed to synthetize all the elements of value (the so called "value flower"), and to identify dimensions that may be overlooked or underappreciated in traditional value assessments (Neumann et al., 2022). As part of this work package, an important factor being considered in the area of broadening of the evidence base are **environmental costs**, namely the impacts for the environment resulting from the development, production, distribution and disposal of health care products. This is the focus of the current report.

# 1.2 Objectives

The **objective of this report** is to illustrate the evidence emerged from conducting a scoping review of the literature that was aimed at exploring the metrics, methods, and approaches that have been proposed or that are currently used to measure the environmental impact of health technologies, and understanding how to integrate such metrics in economic evaluations and HTA.

The **structure of this report** is therefore the following. First, some context information on the rationale for and the need of introducing this pillar within HTA will be provided. Second, the methodology adopted in this work will be thoroughly described. Third, the results, namely the





main insights emerging from the literature review, will be illustrated.

# 2 Background information

# 2.1 Context

The healthcare sector significantly contributes to climate change, accounting for 4.4% of global carbon dioxide (CO2) emissions, the largest among service sectors. Additionally, it generates a substantial amount of waste, including plastics, disposables, and hazardous materials, which can contaminate air, soil, and water (Pichler et al., 2019).

Recognizing the need to address the environmental impact of healthcare, many countries have committed to reducing greenhouse gas emissions from their healthcare systems, and around 50 governments pledged to develop climate-resilient, low-carbon healthcare systems. For instance, the UK National Health Service (NHS) has set targets to achieve net zero carbon emissions by 2040 for direct and indirect emissions (Scope 1 and 2) and by 2045 for Scope 3 emissions from users and suppliers ("Greener NHS," 2020). The European Union (EU) has also proposed enhancing the environmental sustainability of medicines as part of its revised pharmaceutical legislation (European Commission, 2023). Various EU member states, the UK, and Norway have introduced measures or provided guidance to promote a circular economy, and green public procurement is seen as a key strategy to achieve these goals, particularly in the healthcare sector, which accounts for about 9% of government spending across OECD countries.

Discussions have also begun on assessing the environmental impact of specific health technologies and services, with efforts to integrate these considerations into health economic evaluations and Health Technology Assessment (HTA) (Greenwood Dufour et al., 2022; Hensher, 2020; Marsh et al., 2016b; McAlister et al., 2022; Pinho-Gomes et al., 2022; Polisena et al., 2018; Toolan et al., 2023). HTA is a multidisciplinary process used to determine the value of health technologies across their lifecycle, supporting decision-making for equitable, efficient, and high-quality health systems (O'Rourke et al., 2020). Economic evaluations in HTA typically consider both costs and benefits of health technologies, including methods like cost-effectiveness analysis (CEA), cost-utility analysis (CUA), and cost-benefit analysis (CBA) (Drummond, 2015). Given the environmental impact of healthcare, there is growing support for including environmental considerations as an additional criterion in HTA, enabling more comprehensive, evidence-based decision-making regarding the allocation of resources and policy decisions on healthcare access, delivery, and pricing.

HTA agencies globally are beginning to prioritize environmental impacts. For instance, Canada's Drug and Health Technology Agency (CADTH) has included environmental impact in its HTA appraisals and is developing guidelines for conducting these assessments ("CADTH Health Technology Expert Review Panel Deliberative Framework," n.d.). Similarly, the UK's National





Institute for Health and Care Excellence (NICE) is creating a framework to incorporate environmental data into its decision-making processes as part of its 2021-2026 strategy ("NICE strategy 2021 - 2026: dynamic, collaborative, excellent," 2021).

In academia, health and environmental economists are exploring ways to include the environmental impact of health technologies in economic evaluations. Proposals have been made to integrate environmental outcomes into health-related quality of life (HRQOL) measures or to consider them as additional costs (Marsh et al., 2016b). In this context, researchers are continuing to analyze and recommend methods for incorporating these impacts into HTAs.

# 2.2 Objectives

Currently, there are no standardized methods for incorporating the various environmental impacts of health technologies into economic evaluations and HTA from a comprehensive, system-wide perspective that balances priorities across different levels of the value chain (such as policymakers, manufacturers, healthcare providers, patients, caregivers, and future generations). This work seeks to provide a thorough analysis of the methods, approaches, and metrics identified in the literature and by HTA agencies for assessing the environmental impact of health technologies. It examines the current feasibility and potential implications of including these impacts in economic evaluations and HTA, and identifies the requirements for progressing responsibly in this direction.

## 2.3 Definitions

Figure 1 reports some introductory definitions.





#### Figure 1. Introductory definitions

**Greenhouse gases (GHG)**: GHGs are gases that can absorb and emit net heat energy, thus contributing to the warming of the surface of the planet caused by a reduced capacity to cool the warmth received from the sun, also known as the greenhouse effect. The most common GHGs are water vapor, followed by carbon dioxide ( $CO_2$ ), methane, nitrous oxide and ozone, along with fluorinated gases (chlorofluorocarbons, hydrofluorocarbons, perfluorocarbons).

**Carbon footprint**: The total amount of GHG, primarily  $CO_2$ , emitted directly or indirectly in the delivery of health care services over a specific period. Usually, it is expressed in equivalent tons of  $CO_2$ .

**Life Cycle Analysis (LCA)**: Evaluation of the environmental impact of a health technology across all the stages of its life cycle, from cradle to grave, i.e., development, production, use, and disposal. When only specific stages or aspects of the technology's life cycle are evaluated, it is referred to as partial LCA. Two sub-types of LCA proposed and used for assessing environmental impact are the environmentally extended input-output analysis, and the process-based life cycle assessment.

**Environmentally extended input-output analysis (EEIOA)**: Estimation of the environmental impacts (like the carbon footprint) associated with each sector's output using input-output tables, namely tables published by the OECD that quantify in monetary terms, by country and year, the supply chain for all sectors involved in an industry.

**Process-based life cycle assessment (P-LCA)**: Quantification of the environmental impacts (like the carbon footprint) through a series of interlinked processes (characterized by the physical flows of materials and energy inputs and associated environmental emissions) along the life cycle stages of a product or activity.

# 3. Methodology

A scoping review of both scientific and grey literature was conducted following established methodological guidelines and the PRISMA-ScR guidelines . Searches were performed in April 2023 across three electronic databases: PubMed, Web of Science, and Scopus. The search covered titles and abstracts from 2013 to 2023, with no language restrictions. An iterative approach was used to determine the keywords for the search strategy, focusing on two main concepts: "Environmental" and "Health Technology Assessment or economic evaluation" (see Figure 2). The search was broadened beyond health technologies to include related fields, such as bioengineering, to gather additional insights.





## Figure 2. Search strategy

#### Main search concepts, to be combined using "AND":

- Environmental
- Health Technology Assessment, economic evaluation

#### Search concepts synonyms, to be combined using "OR":

Environmental, Carbon emission, Carbon footprint, Greenhouse gas, Water consumption, Waste, Pollution, Life Cycle Cost\*, Life Cycle Assessment, Sustainability Health Technology Assessment, HTA, Economic evaluation, Cost-effectiveness, Budget impact, Budget-Impact, Pricing decision, Price negotiation, Reimbursement, Procurement [or any other correlated term such as: Purchase, Tender(ing)]

Studies were eligible for inclusion if they described a conceptual framework, methodology, or approach used or proposed to integrate the environmental impacts of health technologies into an HTA or economic evaluation, with the goal of supporting various stakeholders in making access or allocation decisions. This was regardless of the specific environmental impacts or the type of technology assessed. No studies were excluded based on their design or language, and relevant literature reviews, editorials, and commentaries were also included. HTA dossiers that considered environmental factors were included as well.

For each selected study, the following information was extracted:

i) Objective, design, and scope of the study;

ii) Methods used to measure the environmental impact of health technologies, including the environmental dimensions considered (e.g., CO2 emissions, water use, waste generation), the approach employed (e.g., full or partial Life Cycle Assessment (LCA)), and the type of impact (direct vs. indirect);

iii) Methods used to incorporate environmental impacts into economic evaluations and HTA, including the level of integration (e.g., as supplementary information, as part of a comprehensive evaluation) or the specific methodology used (e.g., enhanced Cost-Utility Analysis (CUA));

iv) Barriers and facilitators associated with each methodology (used to inform the Discussion section).





# 4. Results

## 4.1 Overview of results

Overall, **16 scientific publications** (De Preux and Rizmie, 2018; Desterbecq and Tubeuf, 2023; Firth et al., 2023; Greenwood Dufour et al., 2022; Guirado-Fuentes et al., 2023; Hensher, 2020; Marsh et al., 2016b, 2016a; McAlister et al., 2022; Ortsäter et al., 2020, 2019; Pekarsky, 2020; Pinho-Gomes et al., 2022; Polisena et al., 2018; Toolan et al., 2023; Walpole et al., 2023) and **6 HTA reports** (*Community water fluoridation programs: a health technology assessment - review of dental caries and other health outcomes*, 2020; Giske et al., 2023; Khangura et al., 2018; NICE, 2022, 2014; Riegelnegg et al., 2023) were selected for data synthesis, as indicated in Figure 3.

## Figure 3. PRISMA Diagram







## 4.2 Overview of the studies

Table 1 and Table 2 report the characteristics of the studies and the HTA dossiers selected for data synthesis.

#### Table 1. Characteristics of selected scientific studies

| Study                      | Title  | Country   | Year | Study type                            | Media outlet                                   |
|----------------------------|--|-----------|------|---------------------------------------|--|
| Marsh et al.               | Expanding Health Technology Assessments to Include<br>Effects on the Environment.  | UK        | 2016 | Methodolog<br>y                       | VIH  |
| Marsh et al.               | Incorporating environmental outcomes into a health economic model.   | UK        | 2016 | Methodolog<br>y                       | IJTAHC   |
| de Preux et al.            | Beyond financial efficiency to support environmental sustainability in economic evaluations.   | UK        | 2018 | CEA                                   | Future<br>Healthcare<br>Journal                |
| Polisena et al.            | Environmental impact assessment of a health technology.  | Canada    | 2018 | Literature<br>review                  | IJTAHC   |
| Ortsäter et al.            | A budget impact model to estimate the environmental impact of adopting RESPIMAT® Re-usable in the Nordics and Benelux.                                       | Sweden    | 2019 | BIA                                   | Advances in<br>Therapy                         |
| Hensher et al.             | Incorporating environmental impacts into the economic evaluation of healthcare systems: Perspectives from ecological economics.                              | UK        | 2020 | Perspective,<br>review,<br>case study | Resources,<br>Conservation<br>and<br>Recycling |
| Ortsäter et al.            | Incorporating the environmental impact into a budget<br>impact analysis: The example of adopting RESPIMAT® re-<br>usable inhaler.                            | Sweden    | 2020 | BIA                                   | AHEHP  |
| Pekarsky et al.            | The inclusion of comparative environmental impact in<br>Health Technology Assessment: Practical barriers and<br>unintended consequences.                     | Australia | 2020 | Editorial                             | AHEHP  |
| Greenwood<br>Dufour et al. | How we might further integrate considerations of<br>environmental impact when assessing the value of health<br>technologies.                                 | Canada    | 2022 | Opinion                               | IJERPH   |
| McAlister et al.           | Incorporating carbon into healthcare: adding carbon emissions to health technology assessments.  | Australia | 2022 | Personal<br>view                      | The Lancet<br>Planetary<br>Health              |
| Pinho-Gomes et<br>al.      | Incorporating environmental and sustainability considerations into health technology assessment and clinical and public health guidelines: a scoping review. | UK        | 2022 | Commentar<br>y                        | IJTAHC   |
| Toolan et al.              | Environmental impact assessment in health technology assessment: principles, approaches, and challenges.   | UK        | 2023 | Perspective                           | IJTAHC   |
| Guirado-<br>Fuentes et al. | Main challenges of incorporating environmental impacts in<br>the economic evaluation of Health Technology<br>Assessment: A scoping review.                   | Spain     | 2023 | Literature<br>review                  | IJERPH   |
| Desterbecq et<br>al.       | Inclusion of environmental spillovers in applied economic evaluations of healthcare products.  | Belgium   | 2023 | Literature<br>review                  | VIH  |
| Walpole et al.             | How can environmental impacts be incorporated in health technology assessment, and how impactful would this be?  | UK        | 2023 | Editorial                             | ERPOR  |
| Firth et al.               | Moving towards a more environmentally sustainable<br>pharmaceutical industry: recommendations for industry<br>and the transition to areen HTA.               | UK        | 2023 | Editorial                             | ERPOR  |





| HTA Agency | Country | Year | HTA dossier title   | Technology<br>assessed  |
|------------|---------|------|---|---|
| NICE       | UK      | 2014 | End-tidal control software for use with Aisys closed<br>circuit anesthesia systems for automated gas control<br>during general anesthesia | Anesthetic  |
| CADTH      | Canada  | 2018 | Composite resin versus amalgam for dental restorations:<br>a health technology assessment   | Medical device<br>(dental resins vs.<br>amalgams)                     |
| CADTH      | Canada  | 2020 | Community water fluoridation programs: a health<br>technology assessment - review of dental caries and<br>other health outcomes           | Public health<br>intervention<br>(community water<br>fluoridation)    |
| NICE       | UK      | 2022 | Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care   | Medical device<br>(compared with<br>intravenous<br>propofol sedation) |
| AIHTA      | Austria | 2023 | Robot-assisted surgery in thoracic and visceral indications – Update 2023   | Medical device<br>(robotic assisted<br>surgery)                       |
| NIPH       | Norway  | 2023 | Triclosan coated sutures for prevention of surgical site infection: a health technology assessment  | Medical device<br>(sutures)   |

#### Table 2 Characteristics of selected HTA dossiers

Abbreviations: CADTH= Canada's Drug and Health Technology Agency; AIHTA=Austrian Institute for Health Technology Assessment; NICE=National Institute for Health and Care Excellence; NIPH= Norwegian Institute of Public Health

# 4.3 Assessment of the environmental impacts of health technologies

Evaluating the environmental impact of health technologies first involves identifying the relevant environmental dimensions. These dimensions are then evaluated using suitable measurement methods (Table 3, Table 4).

Table 3. Identification, assessment and measurement of the environmental impact (when applicable) in





## selected HTA dossiers

| <b>HTA dossiers</b> | Environmental   | Environmental  | Assessment outcome  |
|---------------------|---|--|---|
|                     | dimensions  | assessment methods   |   |
| NICE                | CO <sub>2</sub>   | Literature review of 5 studies   | 144 kg vs. 156 kg of CO2 usage in the End-tidal control<br>vs. manual phase. Consumption savings of fresh gases<br>(oxygen, air, nitrous oxide) from the medical gas<br>supplier not clinically significant between groups.   |
| CADTH               | Mercury   | Literature review of 19<br>studies   | Qualitative evaluation of key risk assessment criteria -<br>namely hazard identification, exposure assessment,<br>and toxicology - for both dental amalgams and resins.   |
| CADTH               | Potential environmental<br>impact (generic)   | Not available  | Not available   |
| NICE                | GHG emission  | Considerations based on<br>company claims  | NA-Company claims that the conservation of gases<br>within Sedaconda ACD-S and using scavenging<br>systems can reduce the release of gases into the<br>atmosphere.  |
| AIHTA               | GHG emission, waste<br>production   | Literature review  | Increased environmental impact (higher greenhouse<br>gas emissions (43.5%) and waste productions (24%) as<br>well as fewer disability-adjusted life years averted per<br>ton of carbon dioxide and waste) of RAS vs.<br>conventional laparoscopic procedures, in line with<br>other studies. This may not sufficiently compensate for<br>the potential clinical benefit of RAS. |
| NIPH                | Environmental pollution<br>(i.e., impact of triclosan-<br>coated sutures on the<br>environment) | Risk assessments from the<br>European Chemicals<br>Agency + Literature<br>review | NA-The triclosan expected to be released in the<br>environment after use in sutures is low. Although<br>undesirable, the environmental impact is likely to be<br>minimal. If the use of triclosan-coated sutures is a<br>valuable, environmental considerations will probably<br>not be an obstacle to use.   |

Abbreviations: CADTH= Canada's Drug and Health Technology Agency; AIHTA=Austrian Institute for Health Technology Assessment; NICE=National Institute for Health and Care Excellence; NIPH= Norwegian Institute of Public Health; CO<sub>2</sub>= carbon dioxide; GHG= greenhouse gas

#### Table 4. Identification, assessment and measurement of the environmental impact (when applicable) in





#### selected scientific publications

| Studies                       | Environmental  | Environmental   | Assessment outcome   |
|-------------------------------|--|---|--|
|                               | dimensions   | assessment methods  |  |
| Marsh et al.                  | CO <sub>2</sub>  | LCA, EEIOA  | Not applicable   |
| Marsh et al.                  | CO <sub>2</sub>  | LCA   | Direct and indirect costs were combined with carbon intensity data, estimates of the average $CO_2$ emissions emitted per GBP spent delivering health services, to estimate the emissions generated as a result of treatment.  |
| de Preux et<br>al.            | CO <sub>2</sub> eq   | Only environmental<br>impact associated to<br>treatment delivery (not<br>LCA) | Tons of CO2eq at the time of treatment initiation and at year 2, for three haemodialysis modalities. Non-traded carbon price of $\pounds$ 52 per ton CO <sub>2</sub> eq used to estimate cost of carbon.   |
| Polisena et<br>al.            | CO <sub>2</sub>  | LCA, EEIOA  | Not applicable   |
| Ortsäter et<br>al.            | PCF  | LCA   | PCF measured as kilos of $CO_2$ eq was derived for each inhaler type accounting the PCF of the whole life cycle (cradle-to-grave)  |
| Hensher et<br>al.             | CO <sub>2</sub> , particulate<br>matter/air pollution,<br>plastic waste, chemical<br>contamination | lca, Eeioa  | Not applicable   |
| Ortsäter et<br>al.            | PCF  | LCA   | PCF measured as kilos of $CO_2$ eq was derived for each inhaler type taking into account the PCF of the whole life cycle (cradle-to-grave)   |
| Pekarsky et<br>al.            | CO <sub>2</sub>  | Not applicable  | Not applicable   |
| Greenwood<br>Dufour et al.    | Not applicable   | Not applicable  | Not applicable   |
| McAlister et<br>al.           | CO <sub>2</sub>  | Process-LCA, EEIOA  | Theoretical-The worldwide reference unit for carbon<br>emissions is $CO_2eq$ , which might be expressed as kg<br>$CO_2eq$ , kilotons $CO_2eq$ , or megatons $CO_2eq$ . A<br>reference unit is used as there are a range of<br>greenhouse gases, with different global warming<br>potentials. |
| Pinho-<br>Gomes et<br>al.     | CO <sub>2</sub>  | LCA, partial LCA  | Not applicable   |
| Toolan et al.                 | CO <sub>2</sub> , biodiversity loss  | Not applicable  | Not applicable   |
| Guirado-<br>Fuentes et<br>al. | Carbon footprint<br>(product, supply chains,<br>healthcare institutions)                           | LCA, EEIOA  | Not applicable   |
| Desterbecq<br>et al.          | CO <sub>2</sub> , water, energy, waste, other  | LCA   | Variable (multiple case studies)   |
| Walpole et<br>al.             | GHG  | LCA   | Not applicable   |
| Firth et al                   | Not applicable   | LCA   | Not applicable   |

Abbreviations: CO<sub>2</sub>= carbon dioxide; GHG= greenhouse gas; LCA= lifecycle analysis; EEIOA= environmentally extended input-output analysis; PCF= product carbon footprint; RAS= robotic assisted surgery.

## 4.4 Integration of the environmental impact in HTA





| Studies                    | Methodologies (either<br>proposed, discussed, or<br>applied)                                       | Main focus of the article   |
|----------------------------|--|---|
| Marsh et al.               | CBA, CUA, MCDA   | Discussing methodological proposal or challenges or both  |
| Marsh et al.               | CUA  | Presenting a case study (on insulin for T2D patients)<br>and discussing challenges with data availability and<br>granularity  |
| de Preux et<br>al.         | CUA  | Presenting a case study on dialysis vs home dialysis  |
| Polisena et al.            | CBA, CUA, MCDA, CEASS<br>framework, weight of<br>evidence, other                                   | Discussing methodological challenges  |
| Ortsäter et al.            | BIA  | Measuring social cost of carbon (in disposable vs.<br>single-use inhalers)  |
| Hensher et al.             | Inclusion of the<br>environmental impact as<br>health gains or costs                               | Comparing proposed methodologies and challenges   |
| Ortsäter et al.            | BIA  | Measuring social cost of carbon measured in   |
| Pekarsky et                | Inclusion of the   | disposable vs. single-use inhalers<br>Discussing methodological challenges (misalignment  |
| al.                        | environmental impact as<br>costs   | between GHG accounting vs. EE methods), regulatory<br>challenges (differential regulatory requirements in EE<br>vs. GHG emission reduction regulations) and<br>challenges in setting incentive schemes. |
| Greenwood<br>Dufour et al. | Criteria to trigger<br>environmental consideration<br>in HTA                                       | Discussing challenges (environmental data<br>availability, responsibilities for data collection)  |
| McAlister et<br>al.        | CBA, CEA, MCDA   | Discussing methodological proposals   |
| Pinho-Gomes<br>et al.      | BIA, CEA, CBA, CUA, MCDA, other  | Elaborating pros and cons of a variety of methodologies, and discussing ethical challenges and political issues   |
| Toolan et al.              | Information conduit, parallel<br>evaluation, integrated<br>evaluation, environmental<br>evaluation | Elaborating on varying levels of integration of the environmental impact in HTA   |
| Guirado-<br>Fuentes et al. | BIA, CBA, CUA, MCDA  | Summarizing evidence from the literature  |
| Desterbecq<br>et al.       | Different EE methodologies,<br>but most characterized as<br>CMA                                    | Summarizing evidence (case studies) from the literature   |
| Walpole et al.             | Inclusion of environmental<br>impact as health gains or<br>costs                                   | Discussing current challenges and providing expert opinion on possible ways forward   |
| Firth et al.               | -  | Discussing challenges (lack of agreement on the<br>approach for environmental action; lack of<br>interdisciplinary collaboration; weak economic, moral,<br>reputational incentives)                     |

Abbreviations: BIA= budget impact analysis; CBA= cost-benefit analysis; CEA= cost-effectiveness analysis; CEASS= comprehensive environmental assessment; CMA=cost-minimization analysis; CUA= cost-utility analysis; EE= economic evaluation; GHG= greenhouse gas; MCDA= multi-criteria decision analysis; T2D=



HORIZON-HLTH-2022-IND-13-03 Grant Agreement No: 101095593



type 2 diabetes

## 4.5 Conclusive remarks

This review, which includes 16 scientific papers and six HTA reports on incorporating the environmental impact of health technologies into HTA, reveals a variety of methodological approaches, demonstrating that it is feasible to measure environmental impact with existing tools (such as LCA). However, there is still no agreement on which specific aspects of environmental impact to measure (such as CO2 emissions, waste management, water or air pollution, or biodiversity loss) or on a standardized method for calculating and integrating these impacts into HTA that would fairly address the needs of all stakeholders across the value chain. Detailed information from the current work will be published in a peer-reviewed paper in a scientific journal.





# References

CADTH Health Technology Expert Review Panel Deliberative Framework, n.d.

Community water fluoridation programs: a health technology assessment - review of dental caries and other health outcomes, 2020. Canadian Agency for Drugs and Technologies in Health.

De Preux, L., Rizmie, D., 2018. Beyond financial efficiency to support environmental sustainability in economic evaluations. Future Healthc J 5, 103–107. https://doi.org/10.7861/futurehosp.5-2-103 Desterbecq, C., Tubeuf, S., 2023. Inclusion of Environmental Spillovers in Applied Economic Evaluations of Healthcare Products. Value in Health 26, 1270–1281. https://doi.org/10.1016/j.jval.2023.03.008

Drummond, M., 2015. Methods for the Economic Evaluation of Health Care Programmes, OUP Oxford. ed.

European Commission, 2023. Reform of the EU pharmaceutical legislation. European Commission. Firth, I., Hitch, J., Henderson, N., Cookson, G., 2023. Moving towards a more environmentally sustainable pharmaceutical industry: recommendations for industry and the transition to green HTA. Expert Review of Pharmacoeconomics & Outcomes Research 23, 591–595. https://doi.org/10.1080/14737167.2023.2214730

Giske, L., Espeland, A., Arentz-Hansen, H., Kleven, L., 2023. Triclosan coated sutures for prevention of surgical site infection: a health technology assessment. Norwegian Institute of Public Health. Greener NHS, 2020.

Greenwood Dufour, B., Weeks, L., De Angelis, G., Marchand, D.K., Kaunelis, D., Severn, M., Walter, M., Mittmann, N., 2022. How We Might Further Integrate Considerations of Environmental Impact When Assessing the Value of Health Technologies. IJERPH 19, 12017. https://doi.org/10.3390/ijerph191912017

Guirado-Fuentes, C., Abt-Sacks, A., Trujillo-Martín, M.D.M., García-Pérez, L., Rodríguez-Rodríguez, L., Carrion I Ribas, C., Serrano-Aguilar, P., 2023. Main Challenges of Incorporating Environmental Impacts in the Economic Evaluation of Health Technology Assessment: A Scoping Review. IJERPH 20, 4949. https://doi.org/10.3390/ijerph20064949

Hensher, M., 2020. Incorporating environmental impacts into the economic evaluation of health care systems: Perspectives from ecological economics. Resources, Conservation and Recycling





## 154, 104623. https://doi.org/10.1016/j.resconrec.2019.104623

Khangura, S., Seal, K., Esfandiari, S., 2018. Composite resin versus amalgam for dental restorations: a health technology assessment. Canadian Agency for Drugs and Technologies in Health.

Marsh, K., Ganz, M., Nørtoft, E., Lund, N., Graff-Zivin, J., 2016a. INCORPORATING ENVIRONMENTAL OUTCOMES INTO A HEALTH ECONOMIC MODEL. Int J Technol Assess Health Care 32, 400–406. https://doi.org/10.1017/S0266462316000581

Marsh, K., Ganz, M.L., Hsu, J., Strandberg-Larsen, M., Gonzalez, R.P., Lund, N., 2016b. Expanding Health Technology Assessments to Include Effects on the Environment. Value in Health 19, 249– 254. https://doi.org/10.1016/j.jval.2015.11.008

McAlister, S., Morton, R.L., Barratt, A., 2022. Incorporating carbon into health care: adding carbon emissions to health technology assessments. The Lancet Planetary Health 6, e993–e999. https://doi.org/10.1016/S2542-5196(22)00258-3

Neumann, P.J., Garrison, L.P., Willke, R.J., 2022. The History and Future of the "ISPOR Value Flower": Addressing Limitations of Conventional Cost-Effectiveness Analysis. Value Health 25, 558–565. https://doi.org/10.1016/j.jval.2022.01.010

NICE, 2022. Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.

NICE, 2014. End-tidal Control software for use with Aisys closed circuit anaesthesia systems for automated gas control during general anaesthesia.

NICE strategy 2021 - 2026: dynamic, collaborative, excellent, 2021.

O'Rourke, B., Oortwijn, W., Schuller, T., the International Joint Task Group, 2020. The new definition of health technology assessment: A milestone in international collaboration. Int J Technol Assess Health Care 36, 187–190. https://doi.org/10.1017/S0266462320000215

Ortsäter, G., Borgström, F., Baldwin, M., Miltenburger, C., 2020. Incorporating the Environmental Impact into a Budget Impact Analysis: The Example of Adopting RESPIMAT® Re-usable Inhaler. Appl Health Econ Health Policy 18, 433–442. https://doi.org/10.1007/s40258-019-00540-0

Ortsäter, G., Borgström, F., Soulard, S., Miltenburger, C., 2019. A Budget Impact Model to Estimate the Environmental Impact of Adopting RESPIMAT® Re-usable in the Nordics and Benelux. Adv Ther 36, 3435–3445. https://doi.org/10.1007/s12325-019-01114-1

Pekarsky, B.A.K., 2020. The Inclusion of Comparative Environmental Impact in Health Technology Assessment: Practical Barriers and Unintended Consequences. Appl Health Econ Health Policy 18, 597–599. https://doi.org/10.1007/s40258-020-00578-5

Pichler, P.-P., Jaccard, I.S., Weisz, U., Weisz, H., 2019. International comparison of health care





carbon footprints. Environ. Res. Lett. 14, 064004. https://doi.org/10.1088/1748-9326/ab19e1 Pinho-Gomes, A.-C., Yoo, S.-H., Allen, A., Maiden, H., Shah, K., Toolan, M., 2022. Incorporating environmental and sustainability considerations into health technology assessment and clinical and public health guidelines: a scoping review. Int J Technol Assess Health Care 38, e84. https://doi.org/10.1017/S0266462322003282

Polisena, J., De Angelis, G., Kaunelis, D., Shaheen, M., Gutierrez-Ibarluzea, I., 2018. ENVIRONMENTAL IMPACT ASSESSMENT OF A HEALTH TECHNOLOGY: A SCOPING REVIEW. Int J Technol Assess Health Care 34, 317–326. https://doi.org/10.1017/S0266462318000351

Riegelnegg, M., Gassner, L., Grössmann-Waniek, N., 2023. Robot-assisted surgery in thoracic and visceral indications – Update 2023. Austrian Institute for Health Technology Assessment.

Toolan, M., Walpole, S., Shah, K., Kenny, J., Jónsson, P., Crabb, N., Greaves, F., 2023. Environmental impact assessment in health technology assessment: principles, approaches, and challenges. Int J Technol Assess Health Care 39, e13. https://doi.org/10.1017/S0266462323000041

Walpole, S.C., Weeks, L., Shah, K., Cresswell, K., Mesa-Melgarejo, L., Robayo, A., Greaves, F., 2023. How can environmental impacts be incorporated in health technology assessment, and how impactful would this be? Expert Review of Pharmacoeconomics & Outcomes Research 1–6. https://doi.org/10.1080/14737167.2023.2248389

